Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism (NephropaedPD01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00776191 |
Recruitment Status :
Terminated
(al study sites stoped on 15/05/2012 because of insufficient recrutement.)
First Posted : October 21, 2008
Last Update Posted : June 4, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Endstage Renal Disease | Drug: Physioneal 35 Drug: Physioneal 40 | Phase 4 |
- Fat oxidation (13C-enrichment in expiration breath samples for U-C13-algae turnover)
- Growth markers (plasma levels of IgF-1, IgF-BP3, leptin)
- Biochemical markers of anabolism (plasma levels of total protein, albumin, transferrin)
- Serum thyroid function (fT3, fT4, TSH)
- Serum lipid status
- Serum markers of calcium/phosphate metabolism (PTH, calcium, ionized calcium, phosphate, alkaline phosphatase)
- Prevalence of metabolic acidosis/ alkalosis (venous sample), serum lactate
- Safety parameters (such as normalized weekly Kt/v, parameters of glucose metabolism, parameters of hepatic function, parameters of calcium-phosphate-metabolism, physical examination incl. standing height, weight, assessment of complications related to peritoneal dialysis as peritonitis, exit infections and inguinal hernia)
- Body composition (lean body mass and body fat mass/fluid)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 5 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized, Multicenter Cross-over Study in Investigating the Effect of Bicarbonate-based Solutions (Physioneal 35 vs. 40) on Protein Metabolism in Children and Adolescents on Chronic Peritoneal Dialysis |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | May 2012 |
Actual Study Completion Date : | May 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Physioneal 35 vs. 40
Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
|
Drug: Physioneal 35
Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
Other Name: Nephropaed-PD-01/B |
Active Comparator: Physioneal 40 vs. 35
Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
|
Drug: Physioneal 40
Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
Other Name: Nephropaed-PD-01/B |
- To demonstrate an increase in protein metabolism during treatment with Physioneal 35® compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis. [ Time Frame: 16 weeks ]
- To demonstrate a improved Fat oxidation during treatment with Physioneal compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis. [ Time Frame: 16 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Months to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who are males or non-pregnant females between the ages of 3 months and 18 years.
- Patients who are on regular automated peritoneal dialysis due to end stage renal failure for at least 3 months.
- Patients and/or their parents must be capable of understanding the purpose and risks of the study.
- Patients and/or their parents (or guardians) who are willing to give written informed consent and willing to participate in and comply with the study protocol.
Exclusion Criteria:
- Use of pure lactate, amino acid or oligosaccharide solutions for peritoneal dialysis
- Peritonitis episode less than 6 weeks before enrolment
- Hypercalcemia (serum) > 2.75 mmol/l in three independent measurements during 10 days
- Severe secondary hyperthyroidism (iPTH > 500 ng/l)
- Renal anemia with hemoglobin (blood) < 10 mg/dl
- Impaired hepatic function (AST/SGOT or ALT/SGPT > 2 times the upper limit of the reference range)
- Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted.
- Pregnant female patients, females of childbearing potential who are unwilling or unable to use adequate contraception methods.
- Severe respiratory insufficiency
- Malnourishment (body weight < -2.5 SDS for height and gender) or severe deterioration of fat metabolism
- Patients with a history of malignancy of any organ system, treated or untreated
-
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the investigational product and the comparator, including
- Major deterioration of the abdominal wall (e.g. dermal infections or burns, hernia)
- Major deterioration of the abdominal cavity (e.g. ascites, ileus, adhesions, bowel perforation, defects of the diaphragm, tumours)
- Patients with a history of viral infections such as HIV or hepatitis B, C.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776191
Germany | |
Pediatric Nephrology, Universiy Children's Hospital | |
Cologne, Germany | |
Dept. of Pediatric Nephrology, University Hospital Erlangen | |
Erlangen, Germany | |
Dept. of Pediatric Nephrology, University of Hannover | |
Hannover, Germany, 30625 | |
Dept. of Nephrology, children´s hospital Memmingen | |
Memmingen, Germany, 87700 | |
Dept. of Nephrology, University of Rostock | |
Rostock, Germany, 18057 |
Principal Investigator: | Joerg Doetsch, Prof. Dr. | University Hospital Erlangen, Department of Pediatrics University Hospital Koeln |
Responsible Party: | University of Erlangen-Nürnberg Medical School |
ClinicalTrials.gov Identifier: | NCT00776191 |
Other Study ID Numbers: |
2005-005434-12 |
First Posted: | October 21, 2008 Key Record Dates |
Last Update Posted: | June 4, 2015 |
Last Verified: | June 2015 |
Physioneal 35 Physioneal 40 children chronic peritoneal dialysis |
Kidney Failure, Chronic Kidney Diseases Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency |